For the quarter ending 2025-06-30, ITOS had $65,709K increase in cash & cash equivalents over the period. -$76,594K in free cash flow.
| Cash Flow | 2025-06-30 |
|---|---|
| Stock-based compensation | 12,516 |
| Net loss | -113,341 |
| Prepaid expenses and other current assets | -833 |
| Accrued personnel expenses | 12,478 |
| Deferred income | -125 |
| Other accrued expenses | 469 |
| Accounts payable | -2,900 |
| Unrealized foreign exchange loss | -415 |
| Depreciation and amortization | 664 |
| Refundable income taxes | 91 |
| Net accretion of available-for-sale debt securities | -4,447 |
| Unrecognized tax benefits | -2,070 |
| Research and development tax credits receivable | 493 |
| Unbilled milestone receivable | 0 |
| Grants receivable | 415 |
| Accrued clinical trial costs | 15,157 |
| Change in operating lease right-of-use assets | -12 |
| Net cash used in operating activities | -76,210 |
| Proceeds from maturities of investments | 225,047 |
| Purchase of property and equipment | 384 |
| Purchase of other assets | 26 |
| Purchases of investments | 89,991 |
| Net cash provided by (used in) investing activities | 134,646 |
| Proceeds from issuance of common stock upon exercise of options and espp purchases | 4,525 |
| Net cash provided by financing activities | 4,525 |
| Effects of exchange rate changes on cash, cash equivalents and restricted cash | 2,748 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 65,709 |
iTeos Therapeutics, Inc. (ITOS)
iTeos Therapeutics, Inc. (ITOS)